DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/058697/acute_myeloid_leuk) has announced the addition of the "Acute Myeloid Leukemia Therapeutics Market (2010 - 2020) (Pipeline Assessment & Market Forecast In G8 Countries)" report to their offering.
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age. Incidence rate of acute myeloid leukemia is high in men and women over 50 years. The acute myeloid leukemia market is segmented into two types; namely childhood acute myeloid leukemia and adulthood acute myeloid leukemia. The market was dominated by AVD regimen in 2010. However, in 2020, the market is expected to be dominated by AVD regimen, Cyatarabine, and Quizartinib drug.
This report studies the market from 2010 to 2020 covering seven major regimens and single drugs (off-patent and pipeline) for acute myeloid leukemia treatment. At present, there are four regimens in the market; namely DC regimen used for induction purpose, DC regimen for elderly patients, VCD, and AVD regimen. Plus, there is a drugs named Cytarabine in the market. Growing population of acute myeloid leukemia is an impetus for the growth of the market. This market is expected to grow at a CAGR of 28.4% from 2015 to 2020. North America was the major contributor to this market; accounting for 68.62% of the total sales of acute myeloid leukemia drugs in 2010; whereas AVD regimen was the major regimen accounting for 54.08% of the total sales of acute myeloid leukemia drugs in 2010. Cytarabine drug is also highly effective in the treatment of acute myeloid leukemia that captured the highly market share of AML market in 2010. Acute myeloid leukemia is still an area with high unmet need for early diagnosis and limited treatment options in this area.
The report studies four existing regimens and single drugs for acute myeloid leukemia market. Currently, there are four major drugs in pipeline for acute myeloid leukemia; which are expecting a market launch by 2012-2014. Quizartinib is currently in phase II pivotal clinical trial for the relapsed/refractory AML patient; which will be launched in the market in 2012 by Ambit Biosciences Inc. Quizartinib has received Orphan Drug designation grant from U.S. FDA and European Union. Besides, the drug has obtained fast track designation in the United States in 2010 for the treatment of FLT3-ITD positive patients with relapsed/refractory AML. The drug is expected to be priced at $25,448 for patients who take them annually.
Key Topics Covered:
- Introduction
- Executive Summary
- Market Overview
- Acute Myeloid Leukemia Market Dynamics
- Acute Myeloid Leukemia Product Market
- Geographical Analysis
- Competitive Landscape
- Company Profiles
Companies Mentioned:
- Ambit Biosciences Corporation
- Celgene Corporation
- Cephalon Inc
- Clavis Pharma Asa
- Eisai Co. Ltd
- Genzyme Corporation
- Sunesis Pharmaceuticals Inc
For more information visit http://www.researchandmarkets.com/research/058697/acute_myeloid_leuk